tradingkey.logo

BRIEF-Valneva Reports Positive Phase 2 Results In Children For Its Chikungunya Vaccine

ReutersJan 22, 2025 5:59 PM

- Valneva SE VLS.PA:

  • VALNEVA REPORTS POSITIVE PHASE 2 RESULTS IN CHILDREN FOR ITS CHIKUNGUNYA VACCINE AND ANNOUNCES PHASE 3 DOSE DECISION

  • VALNEVA SE - TRIAL SHOWS VACCINE WELL TOLERATED BY CHILDREN AGED 1-11 YEARS

  • VALNEVA SE - TO INITIATE PIVOTAL PHASE 3 STUDY IN CHILDREN IN Q4 2025

  • VALNEVA SE - EXPECTS MARKETING APPROVAL IN BRAZIL AND UK IN Q1

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI